Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The internet-related business reported lower revenue due to the impact of the sale of one subsidiary in the previous fiscal year, but profit increased owing to rising demand for IT engineers and steady progress in systems development. The telecommunications business was affected by intensifying competition. The dispensing pharmacy and related businesses were affected by the drug price revision, but profit increased due to an increase in patient visits, higher sales, and reductions in selling, general and administrative expenses.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥8,329 million (YoY -0.4%) |
| Operating profit | ¥-60 million |
| Ordinary income | ¥-57 million |
| Profit attributable to owners of the parent | ¥-34 million |
| Net income per share | ¥(7.36) |
| Operating Margin | △0.7％ |
| Equity ratio | End of the current fiscal period 41.5 / End of previous period 40.6 |
| Total assets | ¥7,220 million |
| Net assets | ¥2,994 million |
| Cash flows from operating activities | ¥128 million |
| Cash flows from investing activities | ¥-256 million |
| Cash flows from financing activities | ¥-474 million |
| Cash and cash equivalents at end of period | ¥2,145 million |
| Full-year earnings forecast | Net Sales ¥8,928 million (YoY +7.2%) / Operating profit ¥159 million / Ordinary income ¥128 million / Net income ¥7 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Internet-related business ¥1,160 million (YoY -9.4%), Telecommunications Business ¥228 million (YoY +49.4%), Dispensing pharmacies and related businesses ¥6,972 million (YoY +0.4%), Other ¥0 million (YoY -97.5%) |
| Segment profit | Internet-related business ¥66 million (YoY +33.0%), Telecommunications Business ¥27 million, Dispensing pharmacies and related businesses ¥363 million (YoY +75.7%), Other ¥-15 million |
| Depreciation and amortization | ¥146,794 thousand |
| Impairment loss | ¥230,306 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社セキュリティーエージェント / Excluded Number of companies 2 / Company name 株式会社ソフィアグローバルワークス, SOPHIA SG MANAGEMENT PTE.LTD. |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 4,677,720 |
| Treasury Shares at Period-End | 49,050 |
| Factors Behind Changes in Business Performance | The internet-related business reported lower revenue due to the impact of the sale of one subsidiary in the previous fiscal year, but profit increased owing to rising demand for IT engineers and steady progress in systems development. The telecommunications business was affected by intensifying competition. The dispensing pharmacy and related businesses were affected by the drug price revision, but profit increased due to an increase in patient visits, higher sales, and reductions in selling, general and administrative expenses. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the internet-related business, the sale of one subsidiary in the previous fiscal year pushed down revenue. The telecommunications business was affected by intensifying competition, while the dispensing pharmacy and related businesses posted higher profit despite the impact of the drug price revision, due to an increase in patient visits and reductions in selling, general and administrative expenses.